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Abstract
Ammonia is a compound that is thought to be central to the pathogenesis of hepatic
encephalopathy. It is an important biomarker and may also serve as a prognostic indi-
cator in acute liver disease where ammonia levels may be predictive of cerebral edema
and herniation. In this chapter, we aim to review and discuss its role in hepatic enceph-
alopathy to include: the cycle within the human body, appropriate measurement and
collection, confounding factors and differential diagnosis, the correlation between levels
and development of encephalopathy, the physiopathology and increased morbidity-
mortality with the incremental rise, clinical utility of sequential measurement, and
lastly, an overview of novel treatments and the tight interconnections with ammonia.
Keywords: ammonia, hepatic encephalopathy, role, pathogenesis, novel treatment
1. Introduction
Ammonia, a colorless gas with a unique odor is thought to be central to the
pathogenesis of hepatic encephalopathy (HE). It is an important biomarker and may
also serve as a prognostic indicator in acute liver disease where ammonia levels may
be predictive of cerebral edema and herniation. In this chapter, we aim to review and
discuss its role in HE understanding its rise and fall as part of the urea cycle, appro-
priate measurement and collection, and examine the paradigms differentiating acute
liver failure with chronic liver disease. We want to recognize other diseases that may
elevate ammonia levels and discuss how different treatments target its reduction.
2. The ammonia cycle within the human body
The homeostasis of ammonia is a multi-organ process involving the brain, gastro-
intestinal tract, muscles, adipose tissue, kidneys, andmainly the liver. A study involv-
ing patients with end-stage liver disease, revealed that branched-chain amino acids
(BCAAs) (Figure 1) are not metabolized in the liver but rather by muscle, kidney,
adipose, and brain tissue. This is in contrast to the aromatic amino acids (tyrosine,
phenylalanine,methionine),which aremetabolized and deaminated solely by the liver.
BCAA supplementation leads to reductions in hyperammonemia as a result of the
metabolism of BCAAs by skeletal muscle. The metabolism of BCAAs supplied carbon
skeletons for the formation of α-ketoglutarate which combined with two ammonia
molecules to form glutamine [1]. In a 1-year double-blind study of 174 patients with
advanced cirrhosis who were randomized to receive BCAAs or equicaloric amounts of
lactoalbumin, the group given BCAAs had a significantly decreased incidence of the
combined endpoint of death and liver decompensation, as well as hospital admissions,
compared with lactoalbumin [2]. In addition, a multi-center randomized study of 646
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patients with cirrhosis whowere given 12 g of BCAAs per day for 2 years, compared
with diet therapy and a defined food intake, found a significant decrease in HE and
refractory ascites in the treatment group [3]. Because of their poor palatability and high
cost, BCAAs are not routinely recommended, but they were important tools in the
proof of concept of liver’s importance in ammonia homeostasis.
The mechanism of how the liver processes the ammonia has been described and
involves the following steps: ammonia is produced by the enterocytes from gluta-
mine and by colonic bacterial catabolism of nitrogenous sources, such as ingested
protein and secreted urea. It then enters the circulation through the portal vein
where the liver metabolizes the majority of the ammonia converting it into urea or
glutamine and preventing entry into the systemic circulation. These were demon-
strated through careful studies of the urea cycle and its disorders [4].
The increase in blood ammonia levels in advanced liver disease is a consequence
of impaired liver function and of shunting of blood around/away from the liver.
Muscle wasting, a common occurrence in these patients, also may contribute since
muscle is also an important site for extrahepatic ammonia removal.
3. Appropriate measurement and collection
The measurement serum ammonia concentration in patients suspected of having
HE remains controversial. While it is well known that venous ammonia levels vary
immensely and are not useful for screening or following HE [5], arterial ammonia
concentrations more accurately correlate with HE as it is further discussed in this
chapter. Furthermore, the grade of HE seems to be more closely related to the
partial pressure of gaseous ammonia (pNH3) than the total arterial ammonia con-
centration, since gaseous ammonia readily enters the brain [6]. This can be easily
calculated with ammonia levels when correlating with pH.
The accuracy of ammonia determination is influenced by many factors, such as
fist clenching, use of a tourniquet, and whether the sample was placed on ice [7]. It
is largely recommended that it is tested within an hour of collection, though some
agents (sodium borate/l-serine) could potentially stabilize for up to 12 h [8].
Thus, ammonia should be collected in an extremity without trauma with arterial
blood, collected in chilled tubes with ammonia-free sodium heparin (green top) or
ethylenediaminetetraacetic acid (EDTA; purple top), placed on ice, and delivered
rapidly to the laboratory (within an hour). Some chemicals could stabilize for
posterior measurement, but more studies are needed to confirm that these agents
will not influence in other reactions and measurements.
4. Correlation of levels and development encephalopathy
Normal values for ammonia concentration may differ depending on age groups. It
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concentration of healthy term infants at birth of 80 to 90 μmol/L, while normal
values in children older than 1 month and adults are less than 50 and 30 μmol/L,
respectively [9].
Early studies had shown a correlation of levels of ammonia and worsening HE up
to two times the upper limit of normality [6]. Further studies have not only
cemented this correlation but have shown a more intricate relationship [10, 11]. It
can predict the risk and frequency of HE episodes [12].
5. The physiopathology and increased morbidity-mortality with the
incremental rise of ammonia
Proof of the role of ammonia in pathogenesis of HE has come from the efficacy
of therapies aimed to lower plasma ammonia in improving its symptoms. The
mechanisms causing brain dysfunction in liver disease are still not known to the full
extent. In coma of models of acute liver failure, the effects of ammonia are present
in brain swelling, impaired cerebral perfusion, and reversible impairment of neu-
rotransmitter systems [13].
Stemming from this proof of concept, several studies have tried to elucidate the
effects of hyperammonemia. First, ammonia is believed to be a direct neurotoxin
potentialized by other toxins, such as mercaptans and short-chain fatty acids [14].
Second, it impairs the blood–brain barrier by changing the protein transport [15].
Third, it increases the intracellular osmolality of astrocytes leading to edema and
extreme cases, herniation [13, 16]. Lastly, it increases oxidative stress. In one study,
oxidative stress markers in the brain of patients with cirrhosis with severe hepatic
encephalopathy included elevated levels of protein tyrosine-nitrated proteins, heat
shock protein-27, and 8-hydroxyguanosine as a marker for RNA oxidation [17].
In a recent study of patients with cirrhosis, there was significant evidence that
ammonia levels correlate with not only the severity of hepatic encephalopathy but
also the failure of other organs in cirrhosis and is an independent risk factor for 28-
day mortality. This data provided evidence that the ammonia level has a clinically
relevant utility in providing important prognostic information, signifying its
potential role as a biomarker in identifying patients at high risk of mortality. A
reduction in ammonia level was associated with improved survival, confirming it as
a potential therapeutic target. Classically in urea cycle disorders ammonia levels
above 200 μmol/L were considered a poor prognostic factor [18], but in this study
in cirrhotics even ≥79.5 μmol/L was associated with increased mortality, indicating
an additional role of ammonia in dictating clinical outcomes [11].
Classically, there was a clear distinction of the harmful effects of the ammonia in
acute liver failure due to the osmotic component [13] and in lesser degree in chronic
liver disease, stating that ammonia in cirrhosis increased morbidity and not mortality.
But newer studies and prospective analysis shows that it can be harmful in similar
way, increasing mortality [11]. Further studies are needed to corroborate both the
utility and prognostic value of ammonia in the setting of chronic liver disease.
6. Confounding factors and differential diagnosis
Ammonia levels may rise due to reasons other than acute or chronic liver dis-
ease. This may include increased urea absorption/production, decreased extra-
hepatic removal, and reduced participation of liver (Table 1).
Processes that increase urea absorption/production are the main conditions that
make up the differential diagnosis. These conditions include gastrointestinal bleed-




Proteus mirabilis), ureterosigmoidostomy, parenteral nutrition, high-dose chemo-
therapy, and systemic Mycoplasma hominis or Ureasplasma spp. infection in lung
transplant recipients.
Within the conditions that decrease extrahepatic removal of ammonia, diseases
affecting the muscles such as severe muscle exertion/heavy exercise are worth
noting.
Reduced participation of liver in the removal of ammonia may occur in any
cause of portosystemic shunting of blood, such as in hereditary hemorrhagic
telangiectasia (Osler-Weber-Rendu disease) and portal hypertension with collateral
formation.
Two other groups of conditions are considered controversial in their role in the
development of hyperammonemia: congenital disorders (certain inborn errors of
metabolism such as urea cycle defects and organic acidemia) and medication
induced (valproic acid, barbiturates, narcotics, diuretics, alcohol, and salicylate-
Reye syndrome). Some authors classify both as a cause for hyperammonemia while
others would englobe in subgroups of liver diseases as they are believed to have
similar pathophysiology [19, 20].
7. Overview on treatments
The treatment HE resonates around decreasing ammonia. It can be achieved
through three major mechanisms: decreasing ammoniagenic substrates, inhibiting
ammonia production, and metabolic removal of ammonia (Table 2).
7.1 Decreasing ammoniagenic substrates: enemas
Enemas are the main treatment of this category. These are administered to
patients at increased risk of aspiration. Different agents have been used, including
Table 1.
Differential diagnosis for elevated ammonia levels.
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tap water, milk/molasses, and lactulose. The efficacy of enema administration has
not been evaluated [19].
7.2 Inhibiting ammonia production: antibiotics (neomycin, paromomycin,
metronidazole, rifaximin, and vancomycin), laxatives (disaccharides-
lactulose/lactitol, polyethylene glycol), and modification of flora
(Lactobacillus SF68, acarbose)
The use of laxatives, especially non-absorbable disaccharides, has been the cor-
nerstone of the treatment HE. Oral lactulose or lactitol (the latter is not available in
the United States) are thought to have an in vitro benefit over other laxatives. This is
due their multi-mechanistic properties. Not only do they cause catharsis but they
convert ammonia to ammonium and also reduce intestinal pH, thereby reducing
ammonia absorption. These agents improve symptoms in patients with acute and
chronic encephalopathy when compared with placebo but do not improve psycho-
metric test performance or mortality. Side effects are common and include abdom-
inal cramping, bloating, flatulence, and electrolyte imbalance.
Oral antibiotics have been used with the aim of modifying the intestinal flora
and lowering stool pH to enhance the excretion of ammonia. Antibiotics are gener-
ally used as second-line agents after lactulose or in patients who are intolerant of
non-absorbable disaccharides. Rifaximin given orally in a dose of 550 mg twice daily
was approved in 2010 for the treatment of chronic hepatic encephalopathy and
reduction in the risk of recurrence of overt encephalopathy in patients with
advanced liver disease. The tolerability and side-effect profile of rifaximin are
superior to those of lactulose, albeit at greater financial cost. Other antibiotics,
including neomycin, paromomycin, metronidazole, and vancomycin, have been
studied in small trials and case series, but some may have an increased side effect
profile and the effectiveness of others are not well established.
Agents that may modify intestinal flora and modulate the generation or intesti-
nal absorption of ammonia have been evaluated as potential treatments. Acarbose,
an intestinal α-glucosidase inhibitor used to treat type 2 diabetes mellitus, inhibits
Table 2.




the intestinal absorption of carbohydrates and glucose and results in their enhanced
delivery to the colon. As a result, the ratio of saccharolytic to proteolytic bacterial
flora is increased and blood ammonia levels are decreased. A randomized controlled
double-blind crossover trial has demonstrated that acarbose improves mild hepatic
encephalopathy in patients with cirrhosis and adult-onset diabetes mellitus. Simi-
larly, probiotic regimens (such as Lactobacillus SF68) have been used to modify
intestinal flora and diminish ammonia generation. Several studies have suggested
that these agents may be beneficial in humans with mild encephalopathy. A
Cochrane Database review in 2011 was unable to conclude that probiotics improve
clinically relevant outcomes [19].
7.3 Metabolic removal of ammonia: ornithine-aspartate (ornithine-
transcarbamylase/zinc), sodium benzoate (phenylbutyrate,
phenylacetate), and dialysis
Sodium benzoate, sodium phenylbutyrate, and sodium phenylacetate, all of
which increase ammonia excretion in urine, are approved by the FDA for the
treatment of hyperammonemia resulting from urea cycle enzyme defects and may
improve HE in patients with cirrhosis. Administration of sodium benzoate, how-
ever, results in a high sodium load, and the efficacy of this agent is not clearly
established [21].
Administration of zinc, which has been used because zinc deficiency is common
in patients with cirrhosis. Furthermore, because it increases the activity of ornithine
transcarbamylase, an enzyme in the urea cycle, it may also improve HE; however,
clear efficacy has not been established. L-ornithine–l-aspartate (LOLA), a salt of the
amino acids ornithine and aspartic acid that activates the urea cycle and enhances
ammonia clearance, has been shown in several randomized controlled studies to
improve HE compared with lactulose; however, this agent is not available in the
United States.
Extracorporeal albumin dialysis using the molecular adsorbent recirculating
system (MARS) has resulted in a reduction in blood ammonia levels and improve-
ment in severe encephalopathy in patients with acute-on-chronic liver failure. Fur-
ther studies are needed to clarify whether albumin dialysis has a role in treatment of
HE [19].
7.4 Treatments on the horizon
Fecal microbiota transplant is being studied prospectively in a few centers in
North America. As an established treatment in C. difficile colitis, this treatment aims
to modify the intestinal flora, as it happens with use of antibiotics, such as
rifaximin.
Studies are currently underway comparing different formulations of rifaximin,
evaluating the difference between the immediate release against the sustained
extended release.
Other antibiotics, cheaper and with safer profiles are being studied prospectively
to compare with the current gold standard, rifaximin. One such antibiotic notably is
nitazoxanide.
Data regarding dialysis as a treatment modality has not been satisfactory in order
to justify its regular use in the setting of HE. There are prospective studies evaluat-
ing other exchange therapies such as plasmapheresis as viable alternative treatment
options especially in the setting of refractory HE.
AST-120, an oral spherical carbonaceous adsorbent approved and used in
chronic kidney disease to decrease uremia by decreasing intestinal indole
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absorption and consequently indoxyl sulfate production [23] has been extrapolated
to HE with promising results, but still in initial phases and further studies are
needed to better characterize its role in the treatment of HE.
8. Conclusions
Our understanding of the interactive physiology between ammonia and HE has
greatly increased since its first proposition by Hippocrates of Kos B.C. and its first
description in 1860 by von Frerichs [22]. There are multiple effective treatments
available and yet others in the horizon. However, there is still much more to be
understood about the role of ammonia in HE and other factors may still be involved
in the pathophysiology of portosystemic encephalopathy. The future of HE appears
bright and future treatment options will hopefully improve the quality of life of
patients with this potentially debilitating disease.
Conflict of interest
The authors declare no conflict of interest.
Appendices and nomenclature
BCAAs branched-chain amino acids
BC before Christ
EDTA ethylenediaminetetraacetic acid
FMT fecal microbiota transplant
HE hepatic encephalopathy
HHT hereditary hemorrhagic telangiectasia
LOLA l-ornithine–l-aspartate
MARS molecular adsorbent recirculating system
pNH3 partial pressure of gaseous ammonia
PSE portosystemic encephalopathy
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